Download a PDF version of this article here.
By Doran Satanove*
3. For Diagnostic Developers, Post-Approval CDx Development Is Economically Preferable to Co-Development
III. Re-Invigorating Patent Protection For Companion Diagnostics Is the Most Efficient Way to Stimulate Companion Diagnostic Microeconomic Growth
D. Patent Law’s Subject Matter Eligibility Doctrine Has Undermined the Prospects of Patenting Companion Diagnostic Tests